These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 23285020)

  • 21. Experimental diabetes mellitus exacerbates tau pathology in a transgenic mouse model of Alzheimer's disease.
    Ke YD; Delerue F; Gladbach A; Götz J; Ittner LM
    PLoS One; 2009 Nov; 4(11):e7917. PubMed ID: 19936237
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characteristics of TBS-extractable hyperphosphorylated tau species: aggregation intermediates in rTg4510 mouse brain.
    Sahara N; DeTure M; Ren Y; Ebrahim AS; Kang D; Knight J; Volbracht C; Pedersen JT; Dickson DW; Yen SH; Lewis J
    J Alzheimers Dis; 2013; 33(1):249-63. PubMed ID: 22941973
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Raphé tauopathy alters serotonin metabolism and breathing activity in terminal Tau.P301L mice: possible implications for tauopathies and Alzheimer's disease.
    Menuet C; Borghgraef P; Matarazzo V; Gielis L; Lajard AM; Voituron N; Gestreau C; Dutschmann M; Van Leuven F; Hilaire G
    Respir Physiol Neurobiol; 2011 Sep; 178(2):290-303. PubMed ID: 21763469
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Age-related impairment of ultrasonic vocalization in Tau.P301L mice: possible implication for progressive language disorders.
    Menuet C; Cazals Y; Gestreau C; Borghgraef P; Gielis L; Dutschmann M; Van Leuven F; Hilaire G
    PLoS One; 2011; 6(10):e25770. PubMed ID: 22022446
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tau accumulation causes mitochondrial distribution deficits in neurons in a mouse model of tauopathy and in human Alzheimer's disease brain.
    Kopeikina KJ; Carlson GA; Pitstick R; Ludvigson AE; Peters A; Luebke JI; Koffie RM; Frosch MP; Hyman BT; Spires-Jones TL
    Am J Pathol; 2011 Oct; 179(4):2071-82. PubMed ID: 21854751
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The potential for beta-structure in the repeat domain of tau protein determines aggregation, synaptic decay, neuronal loss, and coassembly with endogenous Tau in inducible mouse models of tauopathy.
    Mocanu MM; Nissen A; Eckermann K; Khlistunova I; Biernat J; Drexler D; Petrova O; Schönig K; Bujard H; Mandelkow E; Zhou L; Rune G; Mandelkow EM
    J Neurosci; 2008 Jan; 28(3):737-48. PubMed ID: 18199773
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of Pin1 or microtubule binding on dephosphorylation of FTDP-17 mutant Tau.
    Yotsumoto K; Saito T; Asada A; Oikawa T; Kimura T; Uchida C; Ishiguro K; Uchida T; Hasegawa M; Hisanaga SI
    J Biol Chem; 2009 Jun; 284(25):16840-16847. PubMed ID: 19401603
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serine-409 phosphorylation and oxidative damage define aggregation of human protein tau in yeast.
    Vanhelmont T; Vandebroek T; De Vos A; Terwel D; Lemaire K; Anandhakumar J; Franssens V; Swinnen E; Van Leuven F; Winderickx J
    FEMS Yeast Res; 2010 Dec; 10(8):992-1005. PubMed ID: 20662935
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Deletion of the ubiquitin ligase CHIP leads to the accumulation, but not the aggregation, of both endogenous phospho- and caspase-3-cleaved tau species.
    Dickey CA; Yue M; Lin WL; Dickson DW; Dunmore JH; Lee WC; Zehr C; West G; Cao S; Clark AM; Caldwell GA; Caldwell KA; Eckman C; Patterson C; Hutton M; Petrucelli L
    J Neurosci; 2006 Jun; 26(26):6985-96. PubMed ID: 16807328
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aggregation of detergent-insoluble tau is involved in neuronal loss but not in synaptic loss.
    Kimura T; Fukuda T; Sahara N; Yamashita S; Murayama M; Mizoroki T; Yoshiike Y; Lee B; Sotiropoulos I; Maeda S; Takashima A
    J Biol Chem; 2010 Dec; 285(49):38692-9. PubMed ID: 20921222
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Attenuation of synaptic toxicity and MARK4/PAR1-mediated Tau phosphorylation by methylene blue for Alzheimer's disease treatment.
    Sun W; Lee S; Huang X; Liu S; Inayathullah M; Kim KM; Tang H; Ashford JW; Rajadas J
    Sci Rep; 2016 Oct; 6():34784. PubMed ID: 27708431
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phosphorylation of protein Tau by GSK3β prolongs survival of bigenic Tau.P301L×GSK3β mice by delaying brainstem tauopathy.
    Crespo-Biel N; Theunis C; Borghgraef P; Lechat B; Devijver H; Maurin H; Van Leuven F
    Neurobiol Dis; 2014 Jul; 67():119-32. PubMed ID: 24704314
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sex Impact on Tau-Aggregation and Postsynaptic Protein Levels in the P301L Mouse Model of Tauopathy.
    Buccarello L; Grignaschi G; Castaldo AM; Di Giancamillo A; Domeneghini C; Melcangi RC; Borsello T
    J Alzheimers Dis; 2017; 56(4):1279-1292. PubMed ID: 28157099
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Co-localization of alpha-synuclein and phosphorylated tau in neuronal and glial cytoplasmic inclusions in a patient with multiple system atrophy of long duration.
    Piao YS; Hayashi S; Hasegawa M; Wakabayashi K; Yamada M; Yoshimoto M; Ishikawa A; Iwatsubo T; Takahashi H
    Acta Neuropathol; 2001 Mar; 101(3):285-93. PubMed ID: 11307630
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Puromycin-sensitive aminopeptidase (PSA/NPEPPS) impedes development of neuropathology in hPSA/TAU(P301L) double-transgenic mice.
    Kudo LC; Parfenova L; Ren G; Vi N; Hui M; Ma Z; Lau K; Gray M; Bardag-Gorce F; Wiedau-Pazos M; Hui KS; Karsten SL
    Hum Mol Genet; 2011 May; 20(9):1820-33. PubMed ID: 21320871
    [TBL] [Abstract][Full Text] [Related]  

  • 36. GSPE interferes with tau aggregation in vivo: implication for treating tauopathy.
    Santa-Maria I; Diaz-Ruiz C; Ksiezak-Reding H; Chen A; Ho L; Wang J; Pasinetti GM
    Neurobiol Aging; 2012 Sep; 33(9):2072-81. PubMed ID: 22054871
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GFP-Mutant Human Tau Transgenic Mice Develop Tauopathy Following CNS Injections of Alzheimer's Brain-Derived Pathological Tau or Synthetic Mutant Human Tau Fibrils.
    Gibbons GS; Banks RA; Kim B; Xu H; Changolkar L; Leight SN; Riddle DM; Li C; Gathagan RJ; Brown HJ; Zhang B; Trojanowski JQ; Lee VM
    J Neurosci; 2017 Nov; 37(47):11485-11494. PubMed ID: 28986461
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Retarded axonal transport of R406W mutant tau in transgenic mice with a neurodegenerative tauopathy.
    Zhang B; Higuchi M; Yoshiyama Y; Ishihara T; Forman MS; Martinez D; Joyce S; Trojanowski JQ; Lee VM
    J Neurosci; 2004 May; 24(19):4657-67. PubMed ID: 15140937
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Deposition of Phosphorylated α-Synuclein in the rTg4510 Mouse Model of Tauopathy.
    Takaichi Y; Ano Y; Chambers JK; Uchida K; Takashima A; Nakayama H
    J Neuropathol Exp Neurol; 2018 Oct; 77(10):920-928. PubMed ID: 30107539
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neurodegeneration with tau accumulation in a transgenic mouse expressing V337M human tau.
    Tanemura K; Murayama M; Akagi T; Hashikawa T; Tominaga T; Ichikawa M; Yamaguchi H; Takashima A
    J Neurosci; 2002 Jan; 22(1):133-41. PubMed ID: 11756496
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.